[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f8aroy579mv6b":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"medical_code":11,"short_description":12,"alternate_name":11,"disambiguating_description":11,"citations":13,"drugs":25,"specialties":31,"cover":11},904,"dfv6h6751k82n9rs5y2h5e3y","cytochrome-p450-2c19-inhibitors","Cytochrome P450 2C19 Inhibitors",null,"CYP2C19 is a cytochrome P450 monooxygenase that inserts one atom of molecular oxygen into its substrates - polyunsaturated fatty acids - using two electrons supplied by NADPH through cytochrome P450 reductase. Drugs in this class reduce that catalytic activity, so a co-administered drug cleared by CYP2C19 is eliminated more slowly and accumulates. FDA grades the consequence by how far a sensitive index substrate's exposure rises, calling an inhibitor strong at a >=5-fold increase in AUC and moderate at >=2- to \u003C5-fold. A drug belongs here because its recorded effect on CYP2C19 is inhibition, not induction.",[14,20],{"source":15,"licence":16,"source_url":17,"harvested_by":18,"retrieved_at":19},"RxClass (NLM)","US public domain","https:\u002F\u002Frxnav.nlm.nih.gov\u002FREST\u002Frxclass\u002Fclass\u002FbyId.json?classId=N0000182140","load-reference-corpus.cjs","2026-09-13",{"source":21,"licence":22,"source_url":23,"harvested_by":18,"retrieved_at":24},"UniProt Knowledgebase entry P33261 (Cytochrome P450 2C19)","CC BY 4.0 (UniProt Consortium)","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FP33261.json","2026-09-16",[26],{"id":27,"documentId":28,"slug":29,"name":30,"active_ingredient":30,"dosage_form":11,"administration_route":11},1617,"z3qj7dn7uar9os0ns7yis06c","omeprazole","Omeprazole",[]]